Enanta Pharma (ENTA) Misses Q1 EPS Views

Enanta Pharma (NASDAQ: ENTA) reported Q1 EPS of $2.18, $1.64 worse than the analyst estimate of $3.82. Revenue for the quarter came in at $77.5 million versus the consensus estimate of $84.1 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Cash, infrastructure and emerging markets gain ground as large asset owners seek to manage volatility spikes, according to Marsh
• ZWTC 2026 Enters Squad Stage as Zoomex Opens Registration for Competition With Up to 2.5 Million USDT in Prizes